Eye Disease & Ophthalmology Clinical Trials Update: Week 17, 2026

Published April 24, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

This Phase 3 trial is testing a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (nAMD), a common cause of vision loss. If this treatment works as hoped, it could greatly reduce or even eliminate the need for frequent eye injections that patients currently require to manage their condition. The study is recruiting over 700 participants across the US, Europe, and other countries.

Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema

This Phase 4 trial compares two different dosing plans of the drug faricimab for people with diabetic macular edema, a condition that causes swelling in the retina and vision problems. The study is exploring whether a flexible dosing schedule can be as effective as a fixed one, which might reduce how often patients need treatment without sacrificing results. Although the trial is not currently recruiting, its findings could help shape future treatment approaches.

Myopia Control Using Novel Soft Contact Lenses

This study is investigating new types of daily disposable soft contact lenses designed to slow down the progression of nearsightedness (myopia) in children. By potentially controlling how quickly myopia worsens, these lenses could help reduce the risk of serious vision problems later in life. The trial plans to follow children’s eye changes over two years and is preparing to begin recruiting participants.

The Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children

This Phase 3 trial is testing two types of myopia-control contact lenses in children with worsening nearsightedness. Conducted in New Zealand, the study aims to find new ways to slow vision decline in kids over a six-month period with regular eye exams. If successful, this could offer additional options for managing childhood myopia progression.

Effectiveness of tDCS in Paediatric Amblyopia

This trial is exploring the use of transcranial direct current stimulation (tDCS), a non-invasive brain stimulation technique, to improve vision in children aged 4 to 14 with amblyopia, often called lazy eye. For children who do not respond to traditional patching treatments, this could provide a new option to help strengthen their vision. The study is not yet recruiting and aims to enroll 100 participants.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.